Stock PPBT PURPLE BIOTECH LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Purple Biotech Ltd Nasdaq

Equities

PPBT

US74638P1093

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-06-28 EDT 		5-day change 1st Jan Change
0.407 USD -6.99% Intraday chart for Purple Biotech Ltd -17.44% -47.82%
06-27 Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
06-27 Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit CI

Valuation

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Capitalization 1 14.45 67.11 26.87 21.6 13.54 - -
Enterprise Value (EV) 1 14.45 67.11 26.87 21.6 13.54 13.54 13.54
P/E ratio -2.46 x - - - - - -
Yield - - - - - - -
Capitalization / Revenue - 67.1 x - - - - 1.76 x
EV / Revenue - 67.1 x - - - - 1.76 x
EV / EBITDA - - - - - - -
EV / FCF - - -1,603,194 x -1,083,998 x - - -
FCF Yield - - -0% -0% - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 19,561 172,106 184,277 244,589 275,548 - -
Reference price 2 0.7389 0.3899 0.1458 0.0883 0.0454 0.0454 0.0454
Announcement Date 20-02-11 21-03-02 23-02-08 24-03-05 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 1 - - - - - 7.7
EBITDA - - - - - - - -
EBIT 1 - -12.61 - -22.6 -22.27 -15.3 -19.45 -28.2
Operating Margin - -1,261.2% - - - - - -366.23%
Earnings before Tax (EBT) 1 - - -17.83 - - -12 -17 -
Net income 1 -5.85 -28 -18.38 - - -12 -17 -
Net margin - -2,799.9% - - - - - -
EPS -0.3000 - - - - - - -
Free Cash Flow - - - -16.76 -19.93 - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 20-02-11 21-03-02 22-02-09 23-02-08 24-03-05 - - -
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - -
EBITDA - - - - - - - - - - -
EBIT 1 - -5.081 -6.601 -5.122 -5.135 -5.747 -6.267 -4.466 -3.55 -3.35 -3.7
Operating Margin - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - -3 -2 -3
Net income -10.83 - - - - - - - -3 -2 -3
Net margin - - - - - - - - - - -
EPS -0.0600 - - - - - - - - - -
Dividend per Share - - - - - - - - - - -
Announcement Date 22-08-04 22-11-08 23-02-08 23-05-16 23-08-22 23-11-21 24-03-05 24-05-21 - - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - -16.8 -19.9 - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - - - 0.03 0 - - -
Capex / Sales - - - - - - - -
Announcement Date 20-02-11 21-03-02 22-02-09 23-02-08 24-03-05 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PPBT Stock
  4. PPBT Stock
  5. Financials Purple Biotech Ltd